Voyager Therapeutics (VYGR) Stock Statistics & Valuation Metrics

Voyager Therapeutics has a market cap or net worth of $191.57M. The enterprise value is $105.76M.

Voyager Therapeutics has 55,206,886 shares outstanding. The number of shares has decreased by -2.65% in one year.

Voyager Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -24.01%.

The current PE Ratio of Voyager Therapeutics is -5.03. Voyager Therapeutics’s PEG ratio is 0.04.

In the last 12 months, Voyager Therapeutics had revenue of 80.00M and earned -65.00M in profits. Earnings per share was -1.13.

In the last 12 months, operating cash flow was -15.31M and capital expenditures -3.52M, giving a free cash flow of -18.83M billion.

Voyager Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Voyager Therapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Voyager Therapeutics as a current ratio of 5.56, with Debt / Equity ratio of 14.59%

In the past 12 months, Voyager Therapeutics has paid 665.00K in taxes.

Voyager Therapeutics EV to EBITDA ratio is -3.59, with an EV/FCF ratio of -15.90.

Voyager Therapeutics has $266.68M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$222.96M billion.

Gross margin is 55.44%, with operating margin of -104.11%, and net profit margin of -81.25%.

The average price target for Voyager Therapeutics is $14.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy